Clinical Trials Browser

Phase 1/2 × cc-486 × 90 days × Clear all

NCT05141682 2026-03-03

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

Phase 1/2 Active not recruiting

Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic